Skip to content
Menu

Maze Therapeutics, Inc. MAZE

Full chart Compare
Set alert

Price alert · MAZE

All alert types
32.43 USD +1.23 (+3.94%)

Regular-session close

32.46 +0.03 +0.09%

After hours · Nov 19, 4:00 PM ET

30.69 Day range 32.74
21.95 52-week range 53.65
YTD
-21.72%
1 year
-8.75%

5D -0.57 (-1.65%)

3436TueWedThuFriMon33.90
Market cap
1.77B
Revenue (ttm)
20.00M
EPS (ttm)
-2.62
Shares out
54.68M
Forward P/E
-9.76
YTD return
-21.72%
1-year return
-8.75%
50-day average
29.10
200-day average
31.16
Volume
1.00M
Avg volume
716.97K
Open
31.20
Previous close
31.20
Day's range
30.69 – 32.74
52-week range
21.95 – 53.65
Analysts
Strong Buy
Price target
62.46 (+92.6%)
Earnings date
Mar 24, 2027

Key statistics

Enterprise value
1.38B
Price / sales
88.67
Price / book
4.27
Free cash flow
-68.62M
Total cash
389.66M
Total debt
59.64M
Return on equity
-37.49%
Short % of float
14.01%

Fundamental scorecard

4 of 25 checks passed on MAZE’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MAZE Revenue — quarterly 0
MAZE Net income — quarterly -47.97M
MAZE EPS — quarterly -0.79

Earnings

MAZE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 24, 2027Dec 30, 2026-0.85———
Nov 9, 2026Sep 30, 2026-0.75939-0.79-0.03-4.03%
Aug 12, 2026Jun 30, 2026-0.71731-0.76-0.04-5.95%
May 12, 2026Mar 31, 2026-0.43-0.45-0.02-4.65%
Mar 25, 2026Dec 31, 2025-0.73-0.65+0.08+10.96%
Nov 6, 2025Sep 30, 2025-0.74-0.66+0.08+10.81%

Upgrades / downgrades

MAZE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026JP MorganmainOverweightOverweight
Nov 10, 2026WedbushmainOutperformOutperform
Oct 19, 2026Canaccord Genuityinit—Buy
Sep 24, 2026HC Wainwright & Co.reitBuyBuy
Sep 23, 2026Citigroupinit—Buy
Sep 23, 2026WedbushreitOutperformOutperform

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
mazetx.com

News

Your note

Sign in to keep a note on MAZE — it syncs with the Stock Master app.

Insider holders

MAZE insider holders
InsiderRelationLatest transactionDateShares held
BACHRODT AMYOfficerSaleMar 31, 202612,965
BERNSTEIN HAROLDOfficerSaleSep 3, 20260
COLOMA JASON V PH.D.Chief Executive OfficerSaleNov 1, 20260
COURTNEY PHILLIPSGeneral CounselSaleSep 2, 20267,007
DANDEKAR ATULOfficerSaleSep 28, 202632,316
HOMCY CHARLES JDirectorStock GiftMay 3, 202631,113

Institution ownership

MAZE institution ownership
Holder% heldSharesValueReported
Frazier Life Sciences Management, L.P. 9.66%5,282,915171.32MSep 29, 2026
Arch Venture Management, Llc7.53%4,120,053133.61MSep 29, 2026
Deep Track Capital, Lp7.47%4,083,969132.44MSep 29, 2026
TRV GP IV, LLC6.81%3,723,958120.77MSep 29, 2026
Blackrock Inc.6.79%3,712,670120.40MSep 29, 2026
Janus Henderson Group Ltd.6.23%3,408,045110.52MSep 29, 2026

Fund ownership

MAZE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.58%1,411,99045.79MJun 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App1.79%978,32931.73MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.67%913,80229.63MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.43%779,78125.29MSep 29, 2026
JPMorgan Trust II-JPMorgan Small Cap Growth Fund0.77%421,35013.66MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.71%386,84512.55MAug 30, 2026